hereditary breast cancer the implications l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Hereditary Breast Cancer The Implications PowerPoint Presentation
Download Presentation
Hereditary Breast Cancer The Implications

Loading in 2 Seconds...

play fullscreen
1 / 51

Hereditary Breast Cancer The Implications - PowerPoint PPT Presentation


  • 545 Views
  • Uploaded on

Hereditary Breast Cancer The Implications. Kelly-Anne Phillips MBBS MD FRACP CCV Colebatch Clinical Research Fellow Medical Oncologist Peter MacCallum Cancer Centre. Background. Approx 13,000 Australians diagnosed each year

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Hereditary Breast Cancer The Implications' - Rita


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
hereditary breast cancer the implications

Hereditary Breast CancerThe Implications

Kelly-Anne Phillips MBBS MD FRACP

CCV Colebatch Clinical Research Fellow

Medical Oncologist

Peter MacCallum Cancer Centre

background
Background
  • Approx 13,000 Australians diagnosed each year
  • Approx 650 due to genetic susceptibility. Identification of these important because:
    • Their clinical management may differ
    • It may lead to identification of female family members who are at increased cancer risk and who can be targeted for prevention
breast cancer genes
Breast Cancer Genes

Gene% of Hereditary BC

BRCA1 20%

BRCA2 10%

CHEK2 1-5%

P53 <1%

PTEN <1%

ATM <1%

Unknown 65%

slide4

BRCA1 and BRCA2 Cancer Risks

Breast cancer 50%-85%

(often early age at onset)

Second primary breast cancer

Ovarian cancer 10-60%

Increased risk of other cancers (prostate, pancreas, melanoma)

family history is the main clue
Family History Is The Main Clue
  • BC and / or OC in > 2 close relatives on the same side of the family (maternal or paternal)
  • Bilateral breast cancer
  • Early-onset breast cancer
  • Male breast cancer
  • Associated cancers (ovarian)
  • Ethnicity (eg Jewish)
bc pathology is another clue
BC Pathology Is Another Clue
  • BC in BRCA1 carriers are usually:
    • Basal phenotype
    • Hormone receptor negative
    • HER2 negative
    • High grade (high mitotic index)
  • BRCA2-associated BCs do NOT have such a specific phenotype.
additional criteria based on pathology
Additional Criteria Based On Pathology
  • Young (< 40yo) with breast cancer with BRCA1 phenotype
    • Hormone receptor negative
    • HER2 negative
    • Basal markers CK5/6
relevance to woman with recent bc diagnosis
Relevance to Woman With Recent BC Diagnosis

BRCA1/2 mutation

  • If pre-menopausal, HR positive BC, may consider salpingo-oophorectomy as part of BC treatment, to reduce risk of subsequent BC and OC
  • If post-menopausal, may consider salpingo-oophorectomy to prevent subsequent OC

BRCA1/2 mutation and/or strong FHx

  • If prior WLE, may consider completion mastectomy and contralateral risk-reducing mastectomy rather than adjuvant radiation.
  • If retaining breast tissue, may be eligible for medicare funded MRI for ongoing screening
background17
Background
  • Contralateral risk-reducing mastectomy reduces contralateral BC risk by up to 95%
  • Internationally uptake of CRRM for BRCA1 and BRCA2 mutation carriers is reported to vary between 5-38%*
  • What is the prevalence and predictors of CRRM in Australasian women with familial BC?

*Metcalfe K, et al. Int J Cancer 2008;122: 2017-22

slide18

Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer

  • Resource for research
  • Ascertains high risk families with breast and ovarian cancer from Family Cancer Clinics
  • Collect epidemiological data and biological material (fresh tissue, blood )
  • Collection complete from 1,350 breast cancer families – average 9 participants per family.
kconfab follow up project
kConFab Follow-Up Project
  • Follow-up women in kConFab every 3 years
  • Collect data on lifestyle factors, prophylactic surgery and cancer outcomes etc using self-administered questionnaire
results
Results
  • 1018 women with personal history of BC, 30% mutation carriers, median follow-up 11 years
  • 15% underwent CRRM
  • Only 49% who underwent CRRM had breast reconstruction
  • Most (73%) reconstructions occurred within 12 months of CRRM
  • 177 contralateral BCs in 864 women (20%) not electing CRRM
  • 1 chest wall event in 154 women post-CRRM (0.6%)
  • Event rate: 15/1000 women years (no-CRRM) v 0.7/1000 women years (CRRM); p<0.0001
predictors of crrm
Predictors of CRRM

*excludes 22 documented mutation carriers unable to recall if they learnt their mutation status before or after CRRM

conclusions
Conclusions
  • Younger women with more recently diagnosed BC treated with mastectomy are more likely to elect CRRM
  • Neither BRCA1 or BRCA2 mutation status, nor the risks of BC recurrence and death, appears to influence decision making
rationale
Rationale
  • BRCA1 and BRCA2 involved in DNA repair
  • Thus BCs that have no functioning BRCA1 or BRCA2 gene protein, might be more sensitive to chemotherapy agents that break double stranded DNA
  • Also carriers might get more toxicity from treatment that breaks DNA, such as RT and some chemo agents
slide26

Breast Cancer Prognosis In BRCA1 and BRCA2 Mutation Carriers

Results from an International, Prospective, Population-Based Cohort Study

Kelly-Anne Phillips* Frances O’Malley

Pamela Goodwin Roger Milne

Dee West Irene Andrulis

Marguerite Ennis Michael Friedlander

John Hopper Teri Longacre

Esther M. John

Funded by the NHMRC (#145684)U.S National Institutes of Health, (1 RO1 CA102740-01A2, 5 RO1 CA102740-02, 5 RO1 CA102740-03)

* Supported by the Cancer Council Victoria, Colebatch Clinical Research Fellowship

brca prognosis study
BRCA Prognosis Study

Primary Aim

  • To determine whether mutation carriers with BC do better or worse than other women and is that influenced by the type of treatment they receive?
prognosis in hereditary breast cancer31
Prognosis in Hereditary Breast Cancer

Clinical Implications

  • Outcome in BRCA2 carriers was worse than in sporadic cases but this appeared to be explained by them having more adverse traditional prognostic features (node positivity, higher grade)
  • Perhaps BRCA2 carriers should consider preventive approaches rather than relying on screening for early-detection
key points
Key Points
  • BRCA1/2 carriers appear to have equivalent survival compared with non-carriers
  • No excess toxicity of treatment in mutation carriers*
  • Early clinical and preclinical data suggest BRCA1/2 associated BCs may have enhanced susceptibility to platinum agents, but more data are required
  • PARP inhibitors have shown good clinical activity in BRCA1/2 associated BCs in early phase clinical trials
  • BUT CURRENTLY, mutation carriers should receive standard adjuvant systemic therapy, based on features of their tumor, until results of prospective trials available

*Shanley et al Clin Cancer Res 2006

medicare funding of breast mri for high risk women
Medicare Funding of Breast MRI for High Risk Women

Medicare item number 63464.

Annual MRI

Pt must be:

  • referred by specialist
  • <50 years old
  • High risk according to NBOCC criteria
side effects of medical prevention
Side-Effects of Medical Prevention

Reversible / non serious

  • Hot flushes, vaginal discharge/itching, change in periods

Serious

  • Venous thrombosis
  • Endometrial cancer (post-menopausal only)
weighing up the risks vs benefits
Weighing up the Risks vs Benefits
  • For high risk women benefits clearly outweigh risks
  • For 1000 postmenopausal woman at 4% risk of BC over the next 5 years tamoxifen will:
  • For premenopausal woman risks even less, because no endometrial Ca risk
  • Decision aid urgently needed to help individual women assess risk vs benefit, depending on her own personal risk
miss jane hypothetical
Miss Jane Hypothetical
  • 32 yo single magazine editor
  • No medical problems
  • Strong FHx of BC
slide40

64

57

75

6

6

70

12

60

67

59

76

78

58

Ovarian(56)

Breast(42)

Bowel(58)

Breast(62)

(+)

+

?Bowel(67)

44

41

44

40

32

38

42

Breast (40)

_

_

_

+

+

+

+

12

12

10

8

3172

BRCA2 2bp del 6503 (TT)

management of jane
Management of Jane

Current, age 32

  • Doesn’t want surgery. Not confident to rely on screening alone  tamoxifen & screening (annual MRI and mammo, 6 monthly CBE)

Age 42 –

  • Completed 5 yrs tamoxifen. Now married with 2yo twin sons. Not planning further kids, needs contraception. Not keen on mastectomy but undergoes RRSO to reduce both her BC and gynaecologic cancer risk
uptake of prevention options
Uptake of Prevention Options

Not using prevention option 26%

Not using prevention option 43%

BO 54%

BO 39%

BM 3%

BO and BM 16%

BO and chemoprevention 1%

BO and chemoprevention 1%

BM 6%

BO and BM 11%

risk reducing bm
Risk-Reducing BM

17% underwent BM

Average age at BM = 41 years (range 27-66 years)

89% underwent reconstruction

No malignancy found in surgical specimens

Mastectomy type

prophylactic mastectomy uptake
Prophylactic Mastectomy Uptake

COUNTRY

UPTAKE (%)

n

NUMBER OF WOMEN

36.3%

115

317

U.S.A

32.7%

18

55

Netherlands

25.0%

1

4

France

22.4%

88

393

Canada

20.0%

5

25

Austria

17%

29

166

Australia

10.0%

2

20

Italy

4.5%

6

135

Norway

4.2%

4

95

Israel

2.7%

9

339

Poland

Metcalfe et al Int J Cancer 2008

take home points
Take Home Points
  • Assessing FHx cancer in a woman newly diagnosed with BC is important because there may be management implications for her and her family
  • Effective prevention options exist for women at high risk of breast cancer
  • Mx of women at high risk should consider all the surgical and medical prevention options (not just screening!)
  • Mx is complex, changes over time and should be multidisciplinary and evidence-based
  • The Breast Care Nurse can play a vital role in identification of high risk women
do serms reduce bc risk for brca1 2 mutation carriers
Do SERMS Reduce BC Risk For BRCA1/2 Mutation Carriers?

Perhaps not

  • SERMS appeared to only reduce risk of ER positive BCs in the RCTs. BRCA2 BCs usually ER positive but BRCA1 BCs usually ER negative1
  • In NSABP-P1 trial no statistically significant protective effect of tamoxifen (very underpowered analysis)2:

BRCA1 HR 1.67 (95% CI: 0.32-10.7)

BRCA2 HR 0.38 (95% CI: 0.06-1.56)

1Phillips JCO 2000

2King et al JAMA 2001

do serms reduce bc risk for brca1 2 mutation carriers51
Do SERMS Reduce BC Risk For BRCA1/2 Mutation Carriers?

Perhaps

  • BCs in BRCA1 carriers often ER positive during occult phase1
  • Oophorectomy reduces BC risk in BRCA1 and BRCA2 carriers2
  • BCs in BRCA1 carriers often ER beta positive -may be mechanism for tamoxifen response3
  • Retrospective case-control study - tamoxifen reduced risk of contralateral BC in carriers by 50%4

1Li et al Oncogene 2007 2Rebbeck et al JNCI 2009

3Daidone et al JCO 2002 4Gronwald et al Int J Cancer 2006